Author of

• 10583

  +

  P1.06 - Poster Session 1 - Prognostic and Predictive Biomarkers (ID 161)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10629

    +

    P1.06-046 - Prognostic Relevance of the Quantification of Circulating Tumor Cells by mean Epithelial Markers in Advanced Non-Small Cell Lung Cancer Patients. (ID 2817)

    09:30 - 09:30  |  Author(s): S. Muniz-Hernandez
    • Abstract

    Background
    Measurement of CTCs is being increasingly recognized as a promising tool in oncology. Several studies have evaluated CTC in early and locally advance disease; however, few studies have evaluated the prognostic impact of the quantification of CTCs in advanced disease. The aim of this work was to quantify CTCs in peripheral blood through the simultaneous use of three epithelial markers in patients with stages IIIB (pleural effusion) and IV in NSCLC.

    Methods
    Seventy advanced NSCLC patients were included in the study. All patients received platinum-based chemotherapy in first line treatment. Peripheral blood was obtained of each participant, circulating tumor cells were quantified by RT-PCR using three markers: CK-18, CK-19 and CEA. The expression levels of CEA, CK-18 and CK-19 mRNA were quantified from a standard curve using the cDNA obtained from A549 cells. The protocol was registered in ClinicalTrials.gov (NCT01052818).

    Results
    We found a significant statistical correlation between levels of CK-18, CK-19 and CEA mRNA. CTC was lower in patients with oligometastatic disease; higher CTCs determinate by CEA mRNA levels was associated a worse progression-free survival to platinum-based chemotherapy and overall survival.

    Conclusion
    Detection of high CTC numbers by RT-PCR using CEA as a biomarker is useful as a prognostic marker in patients with advanced NSCLC.